Key Points
- CEO Jerrell Shelton sold 28,800 CryoPort shares at an average price of $14.91, generating $429,408. The transaction, conducted under a pre-arranged Rule 10b5-1 plan, reduced his holdings by 2.34% to 1.20 million shares.
- CryoPort recently reported a quarterly loss of $0.20 per share, narrowly missing estimates, while revenue of $48.97 million exceeded expectations. The company remains unprofitable, with a negative net margin of 20.05%.
- Analysts maintain a generally positive view, with seven Buy ratings and two Holds and a consensus price target of $18.00. Institutional investors own 92.9% of the stock, which opened at $14.95 and has traded between $7.61 and $16.89 over the past year.
CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) CEO Jerrell Shelton sold 28,800 shares of CryoPort stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total value of $429,408.00. Following the completion of the transaction, the chief executive officer owned 1,201,814 shares of the company's stock, valued at approximately $17,919,046.74. The trade was a 2.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
CryoPort Trading Up 0.9%
Shares of NASDAQ CYRX opened at $14.95 on Wednesday. The business has a 50 day simple moving average of $15.45 and a 200-day simple moving average of $11.98. CryoPort, Inc. has a twelve month low of $7.61 and a twelve month high of $16.89. The company has a market capitalization of $757.22 million, a price-to-earnings ratio of -16.61 and a beta of 1.89.
CryoPort (NASDAQ:CYRX - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The business had revenue of $48.97 million for the quarter, compared to the consensus estimate of $48.18 million. CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. As a group, equities analysts predict that CryoPort, Inc. will post -0.83 earnings per share for the current year.
Hedge Funds Weigh In On CryoPort
Institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new stake in shares of CryoPort in the 2nd quarter worth about $3,363,000. Evanson Financial LLC acquired a new position in CryoPort during the 2nd quarter valued at about $785,000. Empire Financial Management Company LLC grew its position in CryoPort by 24.4% in the 1st quarter. Empire Financial Management Company LLC now owns 502,575 shares of the company's stock worth $4,161,000 after purchasing an additional 98,714 shares during the last quarter. Quantinno Capital Management LP grew its position in CryoPort by 30.7% in the 1st quarter. Quantinno Capital Management LP now owns 43,966 shares of the company's stock worth $364,000 after purchasing an additional 10,337 shares during the last quarter. Finally, Granahan Investment Management LLC increased its stake in shares of CryoPort by 475.0% in the first quarter. Granahan Investment Management LLC now owns 231,138 shares of the company's stock valued at $1,914,000 after purchasing an additional 190,938 shares during the period. Institutional investors own 92.90% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on CYRX shares. Craig Hallum boosted their price objective on shares of CryoPort from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, June 3rd. Wall Street Zen raised shares of CryoPort from a "sell" rating to a "hold" rating in a report on Monday, May 11th. Guggenheim lifted their target price on CryoPort from $12.00 to $16.00 and gave the company a "buy" rating in a research note on Friday. Roth Capital reaffirmed a "buy" rating and set a $21.00 target price on shares of CryoPort in a report on Friday. Finally, Needham & Company LLC increased their price target on CryoPort from $15.00 to $19.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $18.00.
Check Out Our Latest Stock Report on CYRX
About CryoPort
(
Get Free Report)
CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.
CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
